๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-02-09

Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age (NCT06524882)

A Randomized Trial of Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age

๐ŸŸข Recruiting Phase3 โš™๏ธ Medical Device Protocol Sponsor: Jaeb Center for Health Research

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

Participants eligible for the study will be randomly allocated (1:1:1) to receive either Luminopia dichoptic treatment while wearing optical correction if needed, Vivid Vision dichoptic treatment while wearing optical correction if needed, or continued optical correction alone if needed, with clinical assessments at 9- and 18-weeks post-randomization. At the 18-week primary outcome visit, participants who were randomly assigned to receive optical correction alone if needed with an IOD of 1 logMAR line (5 letters) or more, will be offered randomization to Luminopia or Vivid Vision dichoptic therapy and if they accept, followed forward with visits at 27- and 36-weeks post-randomization. The study will end for all other participants at 18 weeks.

Who can join: Review the eligibility criteria below.

Location: UAB Pediatric Eye Care; Birmingham Health Care โ€” Birmingham, Alabama

Age range: 8 Years to 12 Years

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (58 Sites)

Showing the first 25 of 58 sites.

  • UAB Pediatric Eye Care; Birmingham Health Care โ€” Birmingham, Alabama
  • Midwestern University Eye Institute โ€” Glendale, Arizona
  • Phoenix Children's Medical Group - Ophthalmology โ€” Scottsdale, Arizona
  • University of Arizona โ€” Tucson, Arizona
  • Arkansas Childrens โ€” Little Rock, Arkansas
  • McFarland Eye Care Center โ€” Little Rock, Arkansas
  • University Eye Center at Ketchum Health โ€” Anaheim, California
  • Univ. of California- Berkeley โ€” Berkeley, California
  • Univ of California, Irvine- Gavin Herbert Eye Institute โ€” Irvine, California
  • Stanford University โ€” Palo Alto, California
  • Western University College of Optometry โ€” Pomona, California
  • University of California, Davis โ€” Sacramento, California
  • University of California San Francisco Department of Ophthalmology โ€” San Francisco, California
  • Nova Southeastern University College of Optometry, The Eye Institute โ€” Fort Lauderdale, Florida
  • University of South Florida (USF) Eye โ€” Tampa, Florida
  • Ann & Robert H. Lurie Children's Hospital of Chicago โ€” Chicago, Illinois
  • Illinois College of Optometry โ€” Chicago, Illinois
  • Midwestern University Eye Institute โ€” Downers Grove, Illinois
  • Progressive Eye Care โ€” Lisle, Illinois
  • Indiana School of Optometry โ€” Bloomington, Indiana
  • University of Iowa โ€” Iowa City, Iowa
  • University of Kansas Dept of Ophthalmology โ€” Prairie Village, Kansas
  • Greater Baltimore Medical Center โ€” Baltimore, Maryland
  • Wilmer Eye Institute โ€” Baltimore, Maryland
  • New England College of Optometry โ€” Boston, Massachusetts

๐Ÿ“ž Contact the Study Coordinator

Phone: (813) 975-8690

Email: rkraker@jaeb.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Amblyopia clinical trials

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—